Literature DB >> 24843313

Oxycodone vs. fentanyl patient-controlled analgesia after laparoscopic cholecystectomy.

Boo-Young Hwang1, Jae-Young Kwon1, Eunsoo Kim1, Do-Won Lee1, Tae-Kyun Kim1, Hae-Kyu Kim1.   

Abstract

OBJECTIVES: Oxycodone is semi-synthetic opioid, oral and parenteral preparations have been widely used for acute and chronic pain. The aim of this study was to assess the efficacy and side effects of oxycodone and fentanyl in patient controlled analgesia (PCA) after laparoscopic cholecystectomy.
METHODS: A prospective, randomized, double-blind study was conducted. 81 patients were randomly divided into two groups; fentanyl (10 mcg fentanyl and 1.5 mg ketorolac) and oxycodone group (1 mg oxycodone and 1.5 mg ketorolac). After the operation, a blinded observer assessed pain using a numerical rating scale (NRS), infused PCA dose, side effects, sedation levels, and satisfaction.
RESULTS: Cumulative PCA dose of oxycodone group at 48 h (31.4 ± 16.0 ml) was significantly less than that of fentanyl group (43.8 ± 23.1 ml, P = 0.009). Oxycodone group showed more nausea at 6-24 h after the operation (P = 0.001), but there was no difference in satisfaction score (P = 0.073). There were no significant differences in other side effects, sedation and NRS scores between two groups.
CONCLUSION: Oxycodone showed comparable effects for pain relief compared to fentanyl in spite of less cumulative PCA dose. Based on these results, we could conclude that oxycodone may be useful as an alternative to fentanyl for PCA after laparoscopic cholecystectomy.

Entities:  

Keywords:  Fentanyl; Laparoscopic cholecystectomy surgery; Oxycodone; Patient-controlled analgesia; Postoperative pain.

Mesh:

Substances:

Year:  2014        PMID: 24843313      PMCID: PMC4025163          DOI: 10.7150/ijms.8331

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


Introduction

Laparoscopic cholecystectomy surgery is often accompanied by severe pain, although it has advantages of fast recovery, reduced postoperative pain, and short hospital stay 1,2. Postoperative pain can cause atelectasis, sympathetic over activity, prolonged hospital stay, and decreased patient's satisfaction. Furthermore, unrelieved severe pain may lead to chronic pain. Patient-controlled analgesia (PCA), which allows a patient to administer their own pain relief, is known to provide an efficient way to control postoperative pain 3. A variety of analgesics including non-steroidal anti-inflammatory drugs (NSAIDs) and opioids have been used for the PCA. Not only the efficacy of a drug, but also its side effects, duration, and patient's history or general condition are critical factors to be considered in selecting an opioid. The pharmacodynamic and pharmacokinetic effects depend on the type of opioids, route, age, genetic polymorphism, and so on 4,5. Oxycodone is one of the most widely used opioids for pain management 6,7. There have been several studies on the efficacy and side effects of oxycodone. Oxycodone has been known to have the same potency with morphine 8. Many studies demonstrated good efficacy of oxycodone on postoperative pain 9-11. However, most of the previous studies are based on oral oxycodone and bolus intravenous injection of oxycodone. The equivalent dose of oxycodone to fentanyl has not been clarified, especially in PCA. In this study, we designed a prospective, randomized, and double-blind study to assess the efficacy and side effects of oxycodone PCA compared to those of fentanyl PCA in patients who underwent the laparoscopic cholecystectomy.

Materials and methods

Study design

A prospective, randomized and double-blind study was conducted at the Department of Anesthesia and Pain Medicine at Pusan National University Hospital, Korea between June and October 2013. The study protocol was approved by an appropriate institutional review board (IRB), and patients were provided informed consent before a surgery.

Subjects

90 patients who are ASA class I or II were scheduled for laparoscopic cholecystectomy. Patients of both genders, aged 18 to 65 years old, were selected. Patients, who do not qualify for or do not prefer treatment of opioids or NSAIDs, or who have psychological disorder, chronic pain disorder or preoperative administration of drugs including opioids, antidepressants, gabapentin, pregabalin, and carbamazepine, were excluded. Patients, who cannot use numerical rating scale (NRS), who have increased intracranial pressure, renal failure, hepatic failure, or in pregnancy, were also excluded.

Treatment

The primary end point was to compare efficacy with oxycodone and ketorolac versus fentanyl and ketorolac. Secondary outcomes were incidences of side-effects and patients' satisfaction. Patients were randomly divided into fentanyl group and oxycodone group. Fentanyl group received 10 mcg fentanyl and 1.5 mg ketorolac, and oxycodone group received 1 mg oxycodone and 1.5 mg ketorolac for a bolus dose. Anesthesia was standardized in both groups. 0.2 mg glycopyrrolate was intramuscularly injected to all the patients 30 min before induction of anesthesia. After patients arrived in the operating room, their baseline heart rate, mean arterial blood pressure, oxygen saturation were obtained using patient monitor. Bispectral index (BIS, XP version 4.1; Aspect Medical Systems, Newton, MA, USA) monitoring was used to measure the depth of anesthesia. 2 mg/kg i.v. propofol, 0.6 mg/kg i.v. rocuronium, and 0.5 mcg/kg/min i.v. remifentanil were administered for the induction, and sevoflurane was used for maintenance. 30 mcg fentanyl/4.5 mg ketorolac or 3 mg oxycodone/4.5 mg ketorolac were administered in the fentanyl or the oxycodone groups, respectively, and an antiemetic was administered 30 min before the end of surgery. After the operation, 10 mg i.v. pyridostigmine and 0.4 mg i.v. glycopyrrolate were administered, and patients were transferred to post-anesthesia care unit, and stayed until Aldrete score was greater than 8. Patients received pain control via PCA with a bolus dose of 1 ml, a lock-out interval of 6 min, and a four-hour limit of 40 ml. If patients complained severe pain above 5, we recommended them to press the button instead of administration of rescue analgesics.

Assessment

A blinded observer assessed the pain at rest and during coughing based on an NRS, where 0 denotes no pain and 10 denotes worst pain experienced. Cumulative PCA dose and sedation scale were also measured at 1, 4, 8, 12, 24, and 48 h after the operation. The Ramsay sedation scale was applied to assess the sedation state: 1 = anxious, agitated, or restless; 2 = cooperative, oriented, and tranquil; 3 = responds to command; 4 = brisk response to a light glabellar tap or loud auditory stimulus; 5 = sluggish response to a light glabellar tap or loud auditory stimulus; and 6 = no response to the stimuli. Side-effects were recorded at 6, 24, and 48 h after the surgery. If a patient complained severe nausea, 4 mg i.v. ondansetron was injected. Patients were asked to rank their satisfaction according to the following scale: 1 = very unsatisfactory; 2 = unsatisfactory; 3 = neutral; 4 = satisfactory; 5 = very satisfactory.

Statistical analysis

Data are expressed as mean ± SD. The demographic data were compared using the student's t-test. Incidence of side effects was compared between two groups using the chi-square test and Mann-Whitney test. The cumulative PCA dose and the sedation scores were compared using Mann-Whitney test. The NRS were compared using two-way repeated measures ANOVA. The satisfaction scores of two groups were compared using the chi-square test. A probability of < 0.05 was considered to be significant. SPSS (21.0 IBM statistics data editor SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. An estimated sample size indicated that 41 patients per group would give a β-risk of 80% at an α-level of 0.05 for detecting a difference in cumulative PCA dose (35 vs 40 ml) of at least 5 ml at 48 h after the operation with a standard deviation of 8.0 for each group in the preliminary test. We enrolled 90 subjects for study considering 10% as exclusion rate.

Results

90 patients were assessed for the study. 4 patients refused the participation in the study, and 86 patients were included in this study after randomization. A patient of each group was discharged earlier than expected, and 2 patients of fentanyl group and 1 patient of oxycodone group wanted early discontinuation of PCA for emesis. There was no significant difference between the two groups in the distribution of height, weight, age, and sex (Table 1).
Table 1

Baseline demographic characteristics of patients.

CharacteristicsFentanylOxycodoneTotal
Sex
Male212142
Female192039
Age, mean years (SD)54.4 (13.8)49.6 (15.0)52.0 (14.5)
Weight, mean kg (SD)63.6 (10.865)67.8 (14.2)65.7 (12.7)
Height, mean cm (SD)164.4 (8.909)164.4 (10.4)164.7 (9.6)

There is no significant difference between groups.

Side-effects such as vomiting, headache, shivering, pruritus, and respiratory depression in the oxycodone group were not significantly different from those in the fentanyl group. However, the patients in the oxycodone group experienced more nausea at 6-24 h after operation compared to the fentanyl group (P = 0.002, Table 2).
Table 2

Incidence of side effects.

Side effectsFentanylOxycodoneTotalP value
Nausea, n (%)14 (35)22 (53.7)36 (44.4)0.091
< 6 h14 (35)18 (43.9)32 (39.5)0.413
6 - 24 h5 (12.5)18 (43.9)23 (28.4)0.002
24 h <4 (10)3 (7.3)7 (8.6)0.667
Vomiting0 (0)0 (0)0 (0)-
Headache, n (%)1 (2.5)2 (4.9)3 (3.7)0.571
Shivering, n (%)0 (0)1 (2.4)1 (1.2)0.320
Pruritus, n (%)3 (7.5)1 (2.4)4 (4.9)0.293
Respiratory depression, n (%)0 (0)0 (0)0 (0)-

The oxycodone group patients experienced more nausea at 6-24 h after operation compared to the fentanyl group (P = 0.002, Chi square test).

The cumulative PCA doses were measured at 1, 2, 4, 8, 12, 24, and 48 h after the operation. The oxycodone group showed significantly less amount of cumulative PCA dose compared to the fentanyl group after 8 h (P < 0.05, Figure 1). Cumulative PCA dose of oxycodone group at 48 h (31.4 ± 16.0 ml) was significantly less than that of fentanyl group (43.8 ± 23.1 ml, P = 0.009). Six patients in fentanyl group and ten patients in oxycodone group who complained severe emesis were administrated ondansetron intravascularly. Percentage of severe cases in total nausea of fentanyl group and oxycodone group were 42.9% and 47.6%. There was no significant difference in administration of ondansetron between both groups.
Figure 1

Cumulative PCA dose measured at several time points between 1 and 48 h after the operation. The patients of fentanyl group show higher consumption rate than the patients of oxycodone group. Data are expressed as mean ± SD., *P < 0.05 and **P < 0.01 according to Mann-Whitney test.

Sedation levels of the patients were assessed based on the Ramsey sedation scale. The patients in both groups showed similar sedation levels (Figure 2).
Figure 2

Ramsey sedation scores at several time points between 1 and 48 h after the operation. Both groups show similar sedation levels. Data are expressed as mean ± SD.

There was no significant difference in NRS at rest and during coughing between the two groups and they decreased in process of time from 4 to 48 h (Figure 3a and 3b).
Figure 3

Numerical rating scale (NRS) of pain at 1 - 48 h after the operation. The NRS of pain intensity was assessed (a) at rest and (b) during coughing. There is no significant difference between both groups. Both groups show marked decrease in pain as the time passed. Data are expressed as mean ± SD.

There was no significant difference in satisfaction score at 48 h after the operation (P=0.073, Table 3).
Table 3

Satisfaction on pain management at 48 hr.

Satisfaction, n (%)FentanylOxycodoneTotal
10 (0)0 (0)0 (0)
23 (7.5)0 (0)3 (3.7)
38 (20)7 (17.1)15 (18.5)
422 (55)18 (43.9)40 (49.4)
57 (17.5)16 (39)23 (28.4)

There is no significant difference in satisfaction score at 48 h after the operation between groups (P=0.073, Chi square test).

Discussion

There have been many studies comparing the effect of different opioids on acute post-operative pain. No previous study has compared oxycodone and fentanyl in PCA. We showed that oxycodone group needed less cumulative PCA doses compared to fentanyl group, while analgesic effects were not different. Oxycodone is a semi-synthetic opioid and oral oxycodone has been widely used for treatment for postoperative pain, chronic pain, and pain due to malignant disease 6, 7. Parenteral oxycodone appears to be equipotent with morphine 8. Morphine has a 1:80-100 potency ratio compared to fentanyl 12. In this study, however, the oxycodone group showed significantly less cumulative PCA dose to maintain the NRS values comparable with that of the fentanyl group. Mean cumulative PCA dose of the oxycodone group was 31.4 ml at 48h after operation, while that of the fentanyl group was 43.8 ml. Therefore, we could suggest that the potency ratio of fentanyl to oxycodone might be around 1:75 and oxycodone might be more potent than morphine (4:3). Similarly, there have been several literatures supporting that oxycodone is more potent than morphine. Lenz et al. 10 have suggested that the equianalgesic efficacy of oxycodone is 1.6 times higher than that of morphine. It has been reported that oxycodone provides better analgesia but also more side effects on bolus injection 11. It has also been known that oxycodone have more effective to visceral pain than other opioids 13. Kalso et a l. 14 observed that less oxycodone was needed for the pain relief than morphine. It is too early to conclude that oxycodone of 1 mg is more potent or effective than fentanyl 100mcg or morphine 1mg. We should consider other factors such as distribution, clearance, bioavailability, and duration of the drugs. Kalso et al. 14 also suggested that the parenteral oxycodone provided fast and long-lasting pain relief as compared to morphine. Oxycodone has a slightly longer duration of action when compared with fentanyl (t1/2: 4 h 52 min vs. 3 h 39 min). The analgesic effect of a single dose of i.v. fentanyl may be shorter because of redistribution 11. In this study, the similar analgesic potency was noted during very early postoperative period. Effect of the opioid duration on the PCA consumption is uncertain, because we did not evaluate the time to the first bolus injection after administrating loading dose. There is a possibility that the longer action duration of oxycodone compared to fentanyl saved the cumulative consumption of opioids. The pain intensity of both groups decreased as time went on, thus the cumulative opioid dose also decreased. This result implies that the pain management during the acute phase is critical. Severe acute pain may lead to chronic pain. Therefore, preemptive and aggressive postoperative multimodal analgesia is required 15. Most patients complained of pain during acute phase, and the NRS of the pain intensity was over 5 at 1 h after the operation. Initial bolus doses of oxycodone and fentanyl group were 3 mg and 30 mcg in this study. Therefore, we suggest that bolus dose should be increased or another rescue drugs are necessary in the acute period. Most nausea occurred within 24 h, and it decreased as the time passed. There was no difference in nausea occurrence until 6 h after operation. The nausea before 6 h might be due to inhalation agents, laparoscopic surgery, severe acute pain, gastroparesis, and so on 16. The incidence rate of nausea at 6-24 h after operation in the oxycodone group was higher than that in the fentanyl group although the cumulative PCA dose in the oxycodone group was lower than that in the fentanyl group. Similar to our results, Pedersen et al. 17 demonstrated that morphine and oxycodone produced similar analgesia after percutaneous kidney stone surgery, but the nausea occurred more frequently in the treatment of oxycodone compared to morphine. Low doses of opioids activate mu opioid receptors in the chemoreceptor trigger zone (CTZ), thereby stimulating vomiting. Oxycodone and fentanyl share mu opioid receptor 18. We guess that the longer duration and larger dose administration for bolus injection in oxycodone group induced more frequent nausea. In this study, fifty percents of all patients showed nausea, so it seems to require a routine administration of antiemetics or more careful management of the PCA setting. This result was unexpected that the satisfaction of oxycodone group was similar with fentanyl group although the incidence of nausea was higher in oxycodone group. It might be due to longer duration and higher efficacy for one bolus dose in oxycodone, and nausea subsided quickly by 4 mg i.v. ondansetron. This result implies that oxycodone could be useful for PCA to manage postoperative pain. In this study, ketorolac (1.5 mg/ml in concentration) was mixed to PCA solution. Ketorolac has been known to reduce opioid consumption and opioid related side effects 19. Ketorolac -induced side effects such as increased bleeding tendency and renal toxicity did not occur in this limited number of patients. Maximum cumulative dose of ketorolac were 150 mg and 133 mg in fentanyl and oxycodone group for 48 hrs and did not exceed daily recommended dosage. In this study, the cumulative PCA dose does not mean how many times patients press the button, because we adjusted the lock-out interval as 6 min. If we allowed the patients to shorten lock-out interval, the differences between the cumulative PCA doses of two groups might be widen. In addition, the target of this study was healthy adults in both genders, thus the effects of bioavailability, metabolism, genetic polymorphism, underlying disease, and type of operations have not been investigated. Recent study suggests that there is a significant interindividual variation in the need for oxycodone for sufficient analgesia 20. Therefore, further evaluation and study about oxycodone for PCA should be conducted. Oxycodone showed comparable effects for pain relief compared to fentanyl in spite of less cumulative PCA dose. Based on these results, we could conclude that oxycodone may be useful as an alternative to fentanyl for PCA after laparoscopic cholecystectomy.
  20 in total

Review 1.  Opioid induced nausea and vomiting.

Authors:  Howard S Smith; Andras Laufer
Journal:  Eur J Pharmacol       Date:  2013-10-21       Impact factor: 4.432

2.  Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia.

Authors:  M Silvasti; P Rosenberg; T Seppälä; N Svartling; M Pitkänen
Journal:  Acta Anaesthesiol Scand       Date:  1998-05       Impact factor: 2.105

3.  Analgesic concentrations of oxycodone--a prospective clinical PK/PD study in patients with laparoscopic cholecystectomy.

Authors:  Merja Kokki; Susanna Broms; Matti Eskelinen; Ilpo Rasanen; Ilkka Ojanperä; Hannu Kokki
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-12-29       Impact factor: 4.080

4.  Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study.

Authors:  Camilla Staahl; Georg Dimcevski; Søren Due Andersen; Niels Thorsgaard; Lona L Christrup; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Scand J Gastroenterol       Date:  2007-03       Impact factor: 2.423

Review 5.  Oxycodone for the treatment of postoperative pain.

Authors:  Hannu Kokki; Merja Kokki; Sari Sjövall
Journal:  Expert Opin Pharmacother       Date:  2012-05       Impact factor: 3.889

Review 6.  Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview.

Authors:  Kuntheavy Ing Lorenzini; Youssef Daali; Pierre Dayer; Jules Desmeules
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-11-09       Impact factor: 4.080

7.  Postoperative intravenous morphine consumption, pain scores, and side effects with perioperative oral controlled-release oxycodone after lumbar discectomy.

Authors:  Stephan Blumenthal; Kan Min; Michael Marquardt; Alain Borgeat
Journal:  Anesth Analg       Date:  2007-07       Impact factor: 5.108

8.  Intravenous morphine and oxycodone for pain after abdominal surgery.

Authors:  E Kalso; R Pöyhiä; P Onnela; K Linko; I Tigerstedt; T Tammisto
Journal:  Acta Anaesthesiol Scand       Date:  1991-10       Impact factor: 2.105

9.  A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy.

Authors:  Harald Lenz; Leiv Sandvik; Erik Qvigstad; Carl Eivind Bjerkelund; Johan Raeder
Journal:  Anesth Analg       Date:  2009-10       Impact factor: 5.108

10.  Opioids in anaesthesia: a questionnaire survey in Finland.

Authors:  R Pöyhiä
Journal:  Eur J Anaesthesiol       Date:  1994-05       Impact factor: 4.330

View more
  26 in total

Review 1.  Multimodal Analgesia, Current Concepts, and Acute Pain Considerations.

Authors:  Erik M Helander; Bethany L Menard; Chris M Harmon; Ben K Homra; Alexander V Allain; Gregory J Bordelon; Melville Q Wyche; Ira W Padnos; Anna Lavrova; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2017-01

2.  Comparison of different methods of postoperative analgesia after thoracotomy-a randomized controlled trial.

Authors:  Szymon Bialka; Maja Copik; Andrzej Daszkiewicz; Eva Rivas; Kurt Ruetzler; Lukasz Szarpak; Hanna Misiolek
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

3.  Comparison of oxycodone and fentanyl for postoperative patient-controlled analgesia after laparoscopic gynecological surgery.

Authors:  Joong-Ho Park; Chiu Lee; Youngmin Shin; Ji-Hyun An; Jong-Seouk Ban; Ji-Hyang Lee
Journal:  Korean J Anesthesiol       Date:  2015-03-30

Review 4.  A new therapeutic option for postoperative pain management with oxycodone HCI injection.

Authors:  Byung Moon Choi
Journal:  Korean J Anesthesiol       Date:  2016-06-01

5.  Present-day challenges and future solutions in postoperative pain management: results from PainForum 2014.

Authors:  Kristiina Kuusniemi; Reino Pöyhiä
Journal:  J Pain Res       Date:  2016-02-03       Impact factor: 3.133

6.  A Comparison of Oxycodone and Alfentanil in Intravenous Patient-Controlled Analgesia with a Time-Scheduled Decremental Infusion after Laparoscopic Cholecystectomy.

Authors:  Young Suk Kwon; Ji Su Jang; Na Rea Lee; Seong Su Kim; Young Ki Kim; Byeong Mun Hwang; Seong Sik Kang; Hee Jeong Son; So Young Lim
Journal:  Pain Res Manag       Date:  2016-09-20       Impact factor: 3.037

7.  The analgesic efficacy of oxycodone hydrochloride versus fentanyl during outpatient artificial abortion operation: A randomized trial.

Authors:  Kangjie Xie; Wen Zhang; Wumei Fang; Yanhong Lian; Sufeng Lin; Jun Fang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

Review 8.  Pharmacogenomics of oxycodone: a narrative literature review.

Authors:  Nelly N Umukoro; Blessed W Aruldhas; Ryan Rossos; Dhanashri Pawale; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2021-03-17       Impact factor: 2.533

9.  A Randomized Clinical Trial of Nefopam versus Ketorolac Combined With Oxycodone in Patient-Controlled Analgesia after Gynecologic Surgery.

Authors:  Boo-Young Hwang; Jae-Young Kwon; Do-Won Lee; Eunsoo Kim; Tae-Kyun Kim; Hae-Kyu Kim
Journal:  Int J Med Sci       Date:  2015-07-30       Impact factor: 3.738

10.  Efficacy and tolerability of oxycodone versus fentanyl for intravenous patient-controlled analgesia after gastrointestinal laparotomy: A prospective, randomized, double-blind study.

Authors:  Zhen Ding; Kaiguo Wang; Baosheng Wang; Naibao Zhou; Hao Li; Bo Yan
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.